What this treatment can and cannot do for the patellofemoral joint

The question most patients reach first is practical: can this injection treat cartilage damage behind the kneecap or on the trochlear groove? For suitable focal defects, the answer is that it can be considered — ChondroFiller® is a CE-marked injectable collagen scaffold indicated for focal articular cartilage damage across the knee joint, and the patellofemoral compartment is not excluded from that scope.

Delivered as an ultrasound-guided outpatient injection rather than an arthroscopic or surgical procedure, it works by providing a structural matrix that recruits the body's own progenitor cells to rebuild damaged cartilage tissue progressively over several months.

What the published record does not yet provide is a clinical trial reporting outcomes specifically for patellar or trochlear defects in isolation. Applicability to this compartment rests on the authorised CE indication and clinical inference drawn from broader knee data — a distinction that is worth holding in mind from the outset.

How ChondroFiller works as a regenerative scaffold

Unlike a lubricant or anti-inflammatory injection, ChondroFiller® is an acellular collagen scaffold — meaning no cells are harvested from the patient and no laboratory culture stage is required. The material is a purified Type I collagen derived from murine sources, supplied as a liquid and delivered directly into the cartilage defect during the outpatient appointment.

Once placed, the liquid self-gels within minutes, forming a stable matrix that adheres to the cartilage surface at the defect site. The scaffold then acts as a chemotactic signal: it provides both a physical structure and biological cues that prompt the body's own progenitor cells — resident in the surrounding tissue — to migrate into the gel. Over the following months those cells differentiate into chondrocyte-like cells and begin depositing new matrix. As the repair tissue develops, the collagen scaffold degrades and is progressively replaced. Published studies describe the resulting tissue as hyaline-like rather than fibrocartilage, though the available evidence uses cautious language and compartment-specific data for the patellofemoral joint remains limited.

How it compares with other injections

| Treatment | Primary action | Structural repair? | Tissue type produced | |---|---|---|---| | ChondroFiller® | Scaffold for cell recruitment | Yes (focal defects) | Hyaline-like (published studies) | | Hyaluronic acid | Lubrication / symptom relief | No | — | | Corticosteroid | Anti-inflammatory | No | — | | Microfracture (surgical) | Stimulates marrow cells | Yes (focal defects) | Fibrocartilage |

HA and corticosteroid address symptoms without altering the defect structure; microfracture does target the defect but typically produces fibrocartilage, which is considered biomechanically inferior to native hyaline cartilage. ChondroFiller® aims to bridge that gap within an injection-based, non-surgical pathway.

The outpatient injection procedure

The appointment takes place in a standard clinic setting — no operating theatre, no general anaesthetic, and no overnight admission. ChondroFiller® arrives as a ready-to-use liquid, so there is no prior step involving cell harvest or laboratory preparation; the single session covers both the assessment confirmation and the treatment itself.

Before the scaffold is placed, the treating clinician uses real-time ultrasound imaging to locate the defect precisely and guide the needle to the correct position. Image-guided placement is central to the technique: it allows the clinician to confirm that the collagen liquid is deposited accurately within the defect rather than into the surrounding tissue. Once injected, the material self-gels in situ, as described in the preceding section, without any need for suturing or mechanical fixation.

Intravenous antibiotic prophylaxis is given at the time of the injection as a standard precaution.

How many units are needed?

The amount of scaffold required depends on the size and configuration of the defect, which is established during the clinical assessment rather than on the day of the appointment itself. A single focal defect may require one unit; larger or multi-compartment damage may need two or three. Patients should expect this to be discussed and confirmed before the injection date so that the appropriate quantity is prepared in advance.

After the appointment, a follow-up review is typically scheduled at around six weeks to assess the early response and guide any physiotherapy.

What the clinical evidence shows

Published outcomes data for ChondroFiller® are most mature in the knee, where four clinical studies report mean improvements in standardised knee function (IKDC) scores of approximately 30 points — consistently exceeding the minimum clinically important difference of 16.7 points. The most robust data comes from a prospective post-market cohort study (Jerosch et al.) in which the mean IKDC gain was 32.4 points, sustained and marginally increased at three-year follow-up, with patients reaching an absolute IKDC score of around 80 out of 100.

Structural MRI evidence, measured using MOCART scoring, supports those functional gains. European cohort data report MOCART scores in the range of 81.6 to 84.3, indicating greater than 80% defect filling and good integration of repair tissue with surrounding native cartilage. One study captured progressive maturation within that first year — MOCART improved from 65.3 at four weeks to 81.6 at twelve months — which aligns with the months-long biological timeline described by the mechanism.

Reported complication rates are approximately 0% in published series, and reoperation rates of roughly 3–8% compare favourably with figures reported for ACI and MACI procedures (reoperation rates up to 37% in some series) and microfracture (up to 41%). More than 19,000 cases have been performed globally across CE-indicated joints.

One important qualification applies to all of this evidence: the knee studies pool patients with femoral condyle, tibial plateau, and osteochondral lesion defects rather than reporting patellofemoral cases separately. Patellofemoral applicability is supported by the CE indication covering the whole knee joint and by clinical use, but compartment-stratified outcome data for patellar and trochlear defects specifically have not yet been published. The biomechanical implications of that gap are explored in the following section.

Patellofemoral anatomy and what it means for scaffold treatment

The patellofemoral joint has a mechanical profile that distinguishes it from the rest of the knee. The patella acts as a pulley against the trochlear groove, generating compressive forces that can reach three to four times body weight during activities such as stair climbing or squatting — concentrated over a contact area that shifts continuously as the knee bends. The joint is also subject to shear forces determined by how centrally the patella tracks within its groove.

Both of these factors are relevant to any cartilage scaffold treatment. Scaffold retention and repair tissue maturation depend partly on the local mechanical environment; that environment in the patellofemoral compartment differs from the femoral condyle and tibial plateau settings in which most ChondroFiller® knee studies have been conducted. Published evidence does not yet include outcome data stratified by patellofemoral versus tibiofemoral location, so how the scaffold performs specifically in this compartment has not been independently quantified.

Where patellar maltracking or tilt is present, a scaffold injection alone does not correct the underlying biomechanics. Abnormal tracking concentrates load unevenly across the articular surface, which may affect repair tissue quality and durability over time. Pre-treatment assessment of patellar alignment — including dynamic tracking where relevant — helps establish whether a biomechanical issue warrants attention alongside or before any injection treatment.

ChondroFiller®'s CE indication covers focal articular cartilage defects across the whole knee without compartment exclusion. A 2019 systematic review by Shanmugaraj et al. (Knee Surg Sports Traumatol Arthrosc 27(3):854–67) captured the active and technically demanding nature of cartilage restoration in this compartment — which is itself a reason the evidence base here lags behind condylar repair studies. For patients considering an injectable scaffold for patellar or trochlear damage, the practical implication is that a specialist assessment should address two questions together: whether the defect configuration is suitable for scaffold treatment, and whether the tracking mechanics are stable enough to support durable healing.

Who may be suitable and how to find out

Candidacy for a collagen scaffold injection turns on the nature of the cartilage damage rather than age or activity level alone. ChondroFiller® is designed for focal articular cartilage defects — localised areas of damage rather than the diffuse, widespread joint wear associated with severe osteoarthritis — and defect size, depth, and location are each reviewed during assessment, alongside the patellar tracking and alignment considerations discussed in the previous section.

Some patients present with both cartilage surface damage and pathology of the synovial lining — the separate tissue layer that produces joint fluid and can itself become inflamed or degraded. Where that combination is identified, a synovial hydrogel injection (a different class of treatment that integrates into the joint lining rather than the cartilage surface) may be considered alongside the collagen scaffold in a single outpatient appointment. Because the two products work through different mechanisms on different tissue layers, assessing whether both are indicated forms part of a thorough evaluation rather than a routine add-on.

MRI review to confirm focal defect configuration, and clinical evaluation to identify potential contraindications — including significant malalignment or substantial bone loss beneath the defect — are typically part of the assessment process.

An assessment is the first step to finding out whether this treatment is appropriate for your specific defect. A suitability assessment form is available at amsk.co.uk.